{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-408287","form_type":"8-K","ticker":"JBIO","cik":"0001798749","company_name":"Jade Biosciences, Inc.","filed_at":"2026-09-30T11:13:31+00:00","discovered_at":"2026-09-30T11:15:00.366123+00:00","generated_at":"2026-10-12T13:57:12.952922+00:00","sec_items":["8.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Jade Biosciences reports preclinical JADE301 data in dermatomyositis; Phase 1 in 24 healthy volunteers to start Q4 2026","bullets":["JADE301 binds IFN-β with KD of 11.3 pM, ~2.5-fold higher affinity than the dazukibart comparator, with no detectable binding to other interferon family proteins.","Inhibited pSTAT induction with IC50 of 13 pM (~2.5-fold more potent than dazukibart) and MX-1 in human dermal fibroblasts with IC50 of 11 pM (~8-fold more potent).","NHP data: ~30-day half-life after 30 mg/kg IV (~3x longer than dazukibart) and ~25-day SC half-life; modeled human SC bioavailability ~73%-75% vs dazukibart's ~43%-44%.","GLP NHP toxicology: SC JADE301 every two weeks at 0, 50, 100 and 200 mg/kg was well tolerated; no treatment-related adverse clinical, lab or histopathology findings.","Phase 1 placebo-controlled single ascending-dose SC trial in 24 healthy volunteers to start Q4 2026; interim data anticipated in the second half of 2027."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-408287","json":"https://secwatch.observer/filing/0001193125-26-408287.json","markdown":"https://secwatch.observer/filing/0001193125-26-408287.md","text":"https://secwatch.observer/filing/0001193125-26-408287.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1798749/000119312526408287/0001193125-26-408287-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1798749/000119312526408287/d936098d8k.htm"},"model":{"generated_by":"deepseek-v4.1-flash:cloud@v2","generated_at":"2026-10-12T13:57:12.952922+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}